Literature DB >> 421730

Alterations of phenytoin protein binding with in vivo haemodialysis in dialysis encephalopathy.

W H Steele, J R Lawrence, H L Elliott, B Whiting.   

Abstract

Protein binding of phenytoin was assesed in one patient with dialysis encephalopathy before and after haemodialysis. Phenytoin concentrations were measured by radioimmunoassay and continuous ultrafiltration was used to assess phenytoin binding. At a serum concentration of 60 micromol.1-1 the percentage of phenytoin bound to serum albumin was considerably lower in the patient serum (79.95% predialysis; 92.09% postdialysis) than that in three normal sera (97.90 +/- 0.17%). Analysis of Scatchard plots indicated two classes of binding sites. In class I both the affinity and capacity for binding phenytoin were reduced in the pre and post-dialysis serum, whereas in class II the capacity of the uraemic serum was increased although the intrinsic association constant was greatly reduced. It was concluded that in vivo haemodialysis is associated with large fluctuations in the protein binding of phenytoin, in which the concentration of endogenous dialysible metabolites are strongly implicated.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 421730     DOI: 10.1007/bf00563560

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Effect of in vivo elevation of free fatty acids on protein binding of drugs.

Authors:  R Gugler; D W Shoeman; D L Azarnoff
Journal:  Pharmacology       Date:  1974       Impact factor: 2.547

2.  Diphenylhydantoin side effects and serum albumin levels.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

3.  Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease.

Authors:  W D Hooper; F Bochner; M J Eadie; J H Tyrer
Journal:  Clin Pharmacol Ther       Date:  1974-03       Impact factor: 6.875

4.  Measurement of drug displacement by continuous ultrafiltration.

Authors:  D S Campion; R Olsen
Journal:  J Pharm Sci       Date:  1974-02       Impact factor: 3.534

5.  Alteration of plasma albumin in relation to decreased drug binding in uremia.

Authors:  S W Boobis
Journal:  Clin Pharmacol Ther       Date:  1977-08       Impact factor: 6.875

6.  The effect of haemodialysis on the binding capacity of albumin.

Authors:  S H Dromgoole
Journal:  Clin Chim Acta       Date:  1973-07-27       Impact factor: 3.786

7.  Altered protein binding of diphenylhydamtoin in uremic plasma.

Authors:  M R Blum; S Riegelman; C E Becker
Journal:  N Engl J Med       Date:  1972-01-13       Impact factor: 91.245

8.  Aluminum transfer during hemodialysis.

Authors:  W D Kaehny; A C Alfrey; R E Holman; W J Shorr
Journal:  Kidney Int       Date:  1977-11       Impact factor: 10.612

9.  Aluminium toxicity during regular haemodialysis.

Authors:  H L Elliott; F Dryburgh; G S Fell; S Sabet; A I Macdougall
Journal:  Br Med J       Date:  1978-04-29

10.  Influence of chronic renal failure on protein synthesis and albumin metabolism in rat liver.

Authors:  S B Grossman; S H Yap; D A Shafritz
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

View more
  2 in total

1.  Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease.

Authors:  F Keller; M Maiga; H H Neumayer; H Lode; A Distler
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jul-Sep       Impact factor: 2.441

2.  An Overview of the Protein Binding of Cephalosporins in Human Body Fluids: A Systematic Review.

Authors:  C Jongmans; A E Muller; P Van Den Broek; B De Melo Cruz De Almeida; C Van Den Berg; J Van Oldenrijk; P K Bos; B C P Koch
Journal:  Front Pharmacol       Date:  2022-06-28       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.